A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation
Open Access
- 1 February 2026
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 19 (2)
Abstract
Protein-based pharmaceuticals, such as engineered antibodies, form a major drug class of steadily increasing market share. However, these biologic medicines are costly to manufacture, are subject to strict supply chain and storage constraints, and often require invasive administration routes. Engineered microbes that secrete bioactive products directly within the microbiome milieu may mitigate these challenges. Here, we describe a cell microfactory platform based on the probiotic yeast Saccharomyces boulardii for the production of nanobody biologics in the gastrointestinal (GI) tract. High-level secretion of nanobodies by S. boulardii was achieved by optimizing promoters, secretion signals and antibody formats. In mice, oral gavage of S. boulardii allowed efficient and transient colonization of the colonic compartment, and in situ production of a therapeutic nanobody directed against tumor necrosis factor (TNF). In a mouse model of chemical-induced colitis, GI-delivery of anti-murine TNF nanobody via live S. boulardii improved both survival and disease severity without causing overt perturbation of microbiome composition. These results position S. boulardii as a synthetic biotic platform for the in situ production and delivery of protein-based therapeutics to the GI tract.Keywords
Funding Information
- Weston Family Foundation
- Genome Canada
- Canadian Institutes of Health Research (PJT-180315)
- Canadian Institutes of Health Research (FDN-167277)
- Génome Québec
This publication has 74 references indexed in Scilit:
- Dual engineered bacteria improve inflammatory bowel disease in miceApplied Microbiology and Biotechnology, 2024
- Treatment of murine colitis by Saccharomyces boulardii secreting atrial natriuretic peptideJournal of Molecular Medicine, 2020
- Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardiiProbiotics and Antimicrobial Proteins, 2020
- Genetically engineered probiotic Saccharomyces cerevisiae strains mature human dendritic cells and stimulate Gag-specific memory CD8+ T cells ex vivoApplied Microbiology and Biotechnology, 2019
- Microbiome engineering: Current applications and its futureBiotechnology Journal, 2017
- Dextran Sulfate Sodium (DSS)‐Induced Colitis in MiceCurrent Protocols in Immunology, 2014
- An improved method for whole protein extraction from yeast Saccharomyces cerevisiaeYeast, 2011
- Directed evolution of a secretory leader for the improved expression of heterologous proteins and full‐length antibodies in Saccharomyces cerevisiaeBiotechnology and Bioengineering, 2009
- Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritisArthritis & Rheumatism, 2006
- Responses of human glioblastoma cells to human natural tumor necrosis factor-?: Susceptibility, mechanism of resistance and cytokine production studiesJournal of Neuro-Oncology, 1993